ahlam1399
09-21-2016, 01:40 AM
Allergan buys second fatty liver-disease company
Sept 20 (Reuters) - Allergan Inc on Tuesday said ithad paid $50 million for Akarna Therapeutics Ltd, a privatelyheld company developing treatments for a incurable fatty liverdisease called NASH.http://feeds.feedburner.com/~ff/reuters/mergersNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/mergersNews?a=s3sUTeQNQr0:BqYPD3uwor8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/mergersNews?i=s3sUTeQNQr0:BqYPD3uwor8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/mergersNews?a=s3sUTeQNQr0:BqYPD3uwor8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/mergersNews?i=s3sUTeQNQr0:BqYPD3uwor8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/mergersNews?a=s3sUTeQNQr0:BqYPD3uwor8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/mergersNews/~4/s3sUTeQNQr0
Sept 20 (Reuters) - Allergan Inc on Tuesday said ithad paid $50 million for Akarna Therapeutics Ltd, a privatelyheld company developing treatments for a incurable fatty liverdisease called NASH.http://feeds.feedburner.com/~ff/reuters/mergersNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/mergersNews?a=s3sUTeQNQr0:BqYPD3uwor8:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/mergersNews?i=s3sUTeQNQr0:BqYPD3uwor8:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/mergersNews?a=s3sUTeQNQr0:BqYPD3uwor8:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/mergersNews?i=s3sUTeQNQr0:BqYPD3uwor8:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/mergersNews?a=s3sUTeQNQr0:BqYPD3uwor8:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/mergersNews/~4/s3sUTeQNQr0